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Abstract Purpose To study the extent to which aspira­
tion-sclerotherapy reduces liver volume and whether this 
therapy results in relief of symptoms. Results Four patients, 
group I, with isolated large liver cysts, and 11 patients, 
group II, with polycystic livers, underwent aspiration- 
sclerotherapy. Average volume of aspirated cyst fluid was 
1,044 ml (range 225-2,000 ml) in group I and 1,326 ml 
(range 40-4,200 ml) in group II. Mean liver volume before 
the procedure was 2,157 ml (range 1,706-2,841 ml) in 
group I and 4,086 ml (range 1,553-7,085 ml) in group II. 
This decreased after the procedure to 1,757 ml (range 
1,479-2,187 ml) in group I. In group II there was a sta­
tistically significant decrease to 3,347 ml (range 1,249­
6,930 ml, P =  0.008). Volume reduction was 17.1% 
(range -34.7%  to -4.1% ) and 19.2% (range -53.9%  to 
+2.4%) in groups I and II, respectively. Clinical severity of 
all symptoms decreased, except for involuntary weight loss 
and pain in group II. Conclusion Aspiration-sclerotherapy 
is an effective means of achieving liver volume reduction 
and relief of symptoms.
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Introduction
Isolated liver cysts are very frequent—they have been 
detected in up to 18% of patients subjected to ultrasonog­
raphy or CT scan [1- 3]. Liver cysts have been recognized 
increasingly as the routine use of imaging studies has 
become more widespread. The phenotype of a number of 
inherited syndromes dictates the presence of hepatic cysts. 
Radiographically, hepatic cysts in polycystic livers share 
the same architecture and are thought to arise from aberrant 
bile ducts [4].
Polycystic liver disease (PCLD) is an autosomal inherited 
condition characterized by the presence of numerous cysts 
scattered throughout the liver. There are no, or only a few, 
cysts in the kidneys, which distinguishes it from autosomal 
dominant polycystic kidney disease (ADPKD), the most 
common cause of polycystic liver disease [4]. Although the 
hepatic phenotype of both syndromes is similar, the syn­
dromes are separate entities, as is illustrated by the fact that 
both have different causative genes. PCLD is caused by 
mutations in the PRKCSH gene and the SEC63 gene [5, 6] 
whereas ADPKD is caused by mutations in the PKD-1 and 
the PKD-2 genes [7]. PCLD probably results from ductal 
plate malformation, which is characterized by a disturbance 
in the physiological remodeling of the ductal plate [8]. 
The multiple cysts arise from progressive dilatation of the 
abnormal ducts in biliary hamartomas [4], which are the 
result of ductal plate malformation at the level of the small 
intrahepatic bile ducts. These small bile ducts have lost 
continuity with the remaining biliary tree, which explains 
the non-communicating nature of the cysts in PCLD [9].
Hepatic cysts are rarely symptomatic. Symptoms can arise 
due to growth of the cysts and are usually due to abdominal 
mass; examples include abdominal pain, early satiety, 
dyspnea, nausea, and vomiting and are mostly seen in females
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>50 years of age. Rarely, complications such as portal 
hypertension, cyst infection, and cyst rupture occur [10].
The majority of patients with multiple liver cysts are not 
in need of therapy. When patients become symptomatic, 
therapeutic options should be explored. The aim of therapy 
is to reduce cyst volume in order to achieve relief of 
symptoms and to prevent recurrence. Current management 
consists of aspiration-sclerotherapy of selected cysts or 
surgical approaches aimed at excising or obliterating cysts
[11]. Choice of treatment of PCLD is based on the number, 
size, and location of the cysts and on local expertise.
Aspiration-sclerotherapy is a minor invasive option with 
low morbidity. The technique was first described in 1985
[12] after the realization that aspiration alone led to 100% 
recurrence of cysts [13]. Improvement of this procedure 
consists in additional sclerotherapy with ethanol or other 
irritants (antibiotics), after aspiration of the cyst contents, 
aimed at destroying the cyst lining epithelium [12, 14- 16].
Though this method has slowly gained popularity, it is 
unknown if and to what extent it reduces liver volume, as this 
is arguably the main reason for the development of symp­
toms. Furthermore, it is unknown whether this treatment 
actually benefits patients in terms of relief of symptoms.
To this end we designed this study with two aims in 
mind. First we aimed to evaluate the efficacy of aspiration- 
sclerotherapy in reduction of liver volume. Second we 
wanted to know whether symptoms experienced by patients 
with polycystic liver disease or large isolated hepatic cysts 
were improved by the procedure.
Material and Methods
Subjects
Between October 2004 and May 2007, 15 symptomatic 
patients underwent ultrasonographically guided aspiration- 
sclerotherapy. Patients were subdivided into two groups. 
Group I included four patients with isolated large liver cysts 
(two male, two female, mean age 51.3 years (SD 27.6, range 
24-76 years)). Group II included 11 patients with PCLD, 
defined as >15 liver cysts (all female, mean age 55.0 years 
(SD 12.7, range 35-81 years)). Four patients of group II, 
carried a PRKCSH gene mutation and none of them had a 
SEC63 gene mutation. The study was approved by the local 
medical ethical review committee (CMO regio Arnhem 
Nijmegen). All participants provided informed consent.
Procedure
All aspiration-sclerotherapy procedures to treat liver cysts 
were performed on an out-patient basis. Patients were put
in a supine position. After locating a strategically located 
symptomatic cyst, the overlying skin was locally anaes­
thetized with lidocaine and a small incision was made. We 
performed ultrasound guided aspiration of the cyst with a 5 
French straight catheter needle system or a 7 French pigtail 
needle system. The cyst was emptied via a three-way 
stopcock without allowing air to enter the collapsed cyst. 
After emptying the cyst, we proceeded to instill 96% eth­
anol (to a maximum of 27% of total aspirated volume). We 
usually inject and evacuate ethanol several times in order 
to ensure maximal ablation of the cystic wall. After 15 min 
(range 10-20 min) the procedure was terminated by 
evacuation of all remaining ethanol and removal of the 
catheter. If a patient experienced pain or complete aspira­
tion of cyst fluid was not possible, in most instances 
because of the presence of cystic blood clots, no ethanol 
was instilled into the cyst and the session was abandoned.
Volumetry
Each patient undergoing aspiration-sclerotherapy was 
subjected to two multidetector computed tomography (CT) 
scans, before and after treatment, with a maximum interval 
of 18 months between the scans. Liver volumetry was 
performed on the multidetector CT-scan (Siemens Som­
atom Sensation 64) before the first session and, if there 
were more sessions, after the last session.
The digital CT images with 3 mm slice thickness were 
used for digital volumetry, using the Siemens Volume 
application. The liver was outlined manually, marking each 
1-5 cm with a mouse click until the entire liver perimeter 
was outlined. This step was repeated each 9 mm through 
the complete length of the liver. The software intrapolated 
the intermediate slices and calculated the areas within the 
indicated circumference. Finally, the software calculated 
the liver volume by use of the equation V = S x  A, where
S is the interval of the serial slices (mm) and A is the 
enclosed area (cm ). For comparison, four normal livers 
were evaluated. We measured four livers from four sub­
jects that had had a CT scan for liver-unrelated reasons. 
There the average normal liver volume was 1,550 ml 
(range 1,230-1,751 ml). The average difference between 
intraindividual observations was 35 ml (range 2-85 ml), 
measured in seven livers. That between interindividual 
observations was 52 ml (range 38-72 ml), measured in 
four livers.
Questionnaire
Patients were asked to complete a questionnaire with 12 
abdomen-symptom-specific items. This symptom-based
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questionnaire was focused on the period before, during, and 
after treatment [17]. It is a self-completed questionnaire, 
that has been validated, and can be used in a variety of 
clinical settings. This questionnaire included questions 
about the severity of the symptoms during the previous 
4 weeks rated on a seven-point Likert scale (with 0 
meaning ‘‘absent’’ and 6 ‘‘very severe’’). A score of two or 
more was regarded as symptom presence. Furthermore, 
demographic variables, duration of symptoms, and overall 
severity (on a 100 mm visual analogue scale) were recor­
ded. Questions that were not completed properly were 
excluded from further analysis.
Statistical Analysis
Paired t-tests were performed to study differences between 
liver volume before and after the procedure and the 
severity of symptoms. Pearson’s correlation coefficient was 
used to compare the amount of aspirated fluid and liver 
volume reduction. A difference with a P-value of <0.05 
was considered statistically significant.
Results
Patients
Patient characteristics are shown in Table 1. No session 
was terminated prematurely because of pain.
In total there were six aspiration-sclerotherapy sessions 
in group I and 23 in group II. A total of 30 cysts were 
aspirated in group II. Two patients in group I and five in 
group II were subjected to a single session, while the 
remaining two and six had from two to four sessions. In 
group II, we aspirated a maximum of two cysts during each 
session. Figure 1 shows a typical result of the aspiration- 
sclerotherapy (patient 3). Here, the procedure led to a 
decrease in volume of 11.6%.
The average volume of aspirated cyst fluid was 1,044 ml 
(SD 729, range 225-2,000 ml) in group I and 1,326 ml (SD 
1194, range 40-4,200 ml) in group II. The average amount 
of ethanol instilled in the cysts was 5.7% of aspirated 
volume (range 1.6-13.3%) in group I and 8.3% (range 0.7­
27%) in group II but never more than 50 ml.
Mean clinical follow-up period after the last session was 
21 months (range 8-30 months) for group I and 
14.5 months (range 3-27 months) for group II. Four 
patients, one of group I and three of group II, were referred 
for laparoscopic fenestration because of failure of symp­
toms to improve.
Volumetry
Average liver volume before the procedure, 2,157 ml 
(range 1,706-2,841 ml) in group I and 4,086 ml (range 
1,553-7,085 ml) in group II, was (statistically) much 
higher than that of control livers, because of the large 
volumes of cystic livers. Average liver volume decreased
Table 1 Patient characteristics
a Age reflects current age 
b Indicates a PRKCSH- 
mutation
Sex aegAg Diagnosis Number of Total aspirated CT-volume CT-volume Liver volume
sessions cyst fluid (ml) before (ml) after (ml) change (%)
Group I
1 F 24 Single cysts 2 950 1,801 1,479 -17 .9
2 M 31 Single cysts 2 1,000 2,281 2,187 -4 .1
3 M 74 Single cysts 1 225 1,706 1,508 -11 .6
4 F 76 Single cysts 1 2,000 2,841 1,855 -34 .7
Group II
5b F 40 PCLD 4 1,310 5,489 4,974 -9 .4
6b F 58 PCLD 4 505 4,897 4,145 -15 .4
7 F 65 PCLD 1 40 1,553 1,441 -7 .2
8 F 81 PCLD 1 1,400 3,004 2,424 -19.3
9b F 55 PCLD 1 1,300 4,195 2,877 -31 .4
10b F 35 PCLD 3 980 4,275 4,376 +2.4
11 F 61 PCLD 2 1,100 2,809 2,164 -23 .0
12 F 45 PCLD 1 500 6,959 6,930 -0 .4
13 F 60 PCLD 2 4,200 7,085 4,637 -34 .6
14 F 57 PCLD 1 200 1,974 1,603 -18 .8
15 F 48 PCLD 3 3,050 2,707 1,249 -53 .9
Ô  Springer
2254 Dig Dis Sci (2008) 53:2251-2257
to 1,757 ml (range 1,479-2,187 ml) in group I and 
3,347 ml (range 1,249-6,930 ml) in group II after the 
procedures. This represents a reduction of volume of 17.1% 
(range -34.7%  to -4.1% ) in group I and 19.2% (range 
-53.9%  to +2.4%) in group II. Liver volume reduction 
reached statistical significance in group II with a mean liver 
volume decrease of 739 ml (95%CI 236-1,241 ml, 
P =  0.008). Liver volume decreased in all patients of 
group I and in nine patients in group II. One patient had 
only a slight decrease of liver volume and one patient had a 
slight increase.
There was an excellent, significant, correlation between 
the volume removed by cyst aspiration and the final liver 
volume as assessed on follow-up CT scanning. In essence, 
larger volume on aspiration led to better results in terms of 
liver volume reduction (r =  -0 .87 P <  0.0001) (Fig. 2).
Questionnaire
The response to the questionnaire was 100%. Table 2 shows 
the average degree of symptoms during treatment. There 
were two patients, both of group II, which did not experi­
ence any pain during treatment. Nausea and vomiting was 
noted by three patients, two of group I and one of group II.
1000 -
Aspirated cyst volume (ml)
1000 2000 3000 4000 5000
-3000 J
Fig. 2 Relationship between total aspirated cyst fluid and the liver 
volume (r =  -0 .86 , P  <  0.0001)
Table 3 displays the average degree of symptoms before 
and after treatment. In both groups, the clinical severity of all 
symptoms decreased, except for involuntary weight loss and 
pain in group II. Specifically, the severity of postprandial 
fullness and abdominal distension decreased more than that 
of the other symptoms. Most patients of both groups expe­
rienced a decrease of all listed symptoms, although some 
patients had an increase of one of the symptoms after 
treatment. Total pain increased in four patients (all in group 
II), was stable in three (one in group I and two in group II), 
while the remaining patients had a decrease in total pain.
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Table 2 The average severity of symptoms during treatment
Symptoma Group I Group II
1. Pain
Insertion of catheter 2.7 2.0
During aspiration 2.8 1.5
During ethanol instillation 1.8 2.2
2. Nausea 0.9 0.5
3. Vomiting 0.7 0.3
a Symptoms were scored on a range of 0-6 (0 =  no symptom;
6 =  very severe)
None of the differences reached the level of statistical 
significance.
Discussion
We found that aspiration-sclerotherapy in patients with 
liver cysts leads to a substantial reduction of liver volume 
and a corresponding decline of symptoms. It is minimally 
invasive and safe, can be done on an out-patient basis, and 
complications are rare. The therapy is effective for single 
liver cysts and for polycystic livers with large cysts, 
because it reduces liver volume and probably relieves
Table 3 Average severity of symptoms before and after treatment
Symptoma Group I 
Before After
Group II 
Before After
1. Abdominal pain 
General 1.7 1.0 0.9 0.6
Postprandial 1.7 0.7 1.0 0.4
Fasting 1.3 0.7 0.6 0.3
Unrelated to defecation 0.7 0 0.8 0.3
2. Epigastric pain 
General 1.2 0.3 1.7 1.5
During daytime 0.8 0.2 1.5 1.5
At night/asleep 1.0 0.3 1.4 1.4
3. Heartburn 0 0 1.6 1.0
4. Regurgitation 0 0 1.6 1.2
5. Nausea 0.7 0.3 1.1 1.0
6. Vomiting 0.7 0.3 0.2 0.2
7. Loss of appetite 1.2 0.5 1.5 1.2
8. Postprandial fullness 1.3 0.8 3.0 2.1
9. Shortness of breath 0.7 0.2 1.0 0.7
10. Abdominal distension 2.0 0.7 3.2 1.7
11. Involuntary weight loss 0.3 0 0.3 0.7
12. Pain 2.1 1.3 1.4 1.6
a Symptoms were scored on a range of 0-6 (0 =  no symptom, 
6 =  very severe)
symptoms. This will make aspiration-sclerotherapy part of 
the armamentarium to treat PCLD and large solitary liver 
cysts.
We evaluated four livers with a single cyst and 11 
polycystic livers. The procedure as described in this study 
resulted in an average liver volume reduction of 17.1% and 
19.2%, respectively. We elected not to treat patients with 
small liver cysts as it is unlikely this would result in sub­
stantial reduction of liver volume.
An interesting difference between the two groups is the 
total liver volume. The volumes of livers with a single cyst, 
are smaller than polycystic livers. We found that the effi­
cacy of the aspiration-sclerotherapy in terms of liver 
volume reduction was similar in both groups.
We evaluated total liver volume rather than individual 
cysts, because symptoms in, especially, patients with 
polycystic livers arise from compression by severe hepa­
tomegaly rather than the volume effect of a single 
strategically located cyst. As such, our study stands out 
because previously studies recorded the size of individual 
cysts rather than total liver volume. Liver volume mea­
surement is used for the work-up for liver transplant. In 
our hands the measurement was reproducible, and had 
limited intra and interoperator variability. Although the 
procedure is currently not used in clinical practice it 
provides highly useful information and in the near future 
might be used to tailor the treatment options for PCLD 
[18- 20].
The efficacy of the aspiration-sclerotherapy exceeded 
our expectation and could be achieved in all except a single 
patient of group II. The liver volume of this patient 
increased with by 2%, despite an aspirated volume of 
980 ml. At the moment it is uncertain why this single cyst 
was refractory to treatment. She was among two other 
patients of group II and one of group I who were referred 
for subsequent laparoscopic cyst fenestration.
We learned from our study that it is far more effective to 
evacuate large liver cysts (arbitrarily defined as >8 cm) as 
these lead to a significantly better volume reduction 
(Fig. 2). On the other hand, repeated (2-3) aspirations of 
these cysts are necessary to yield an acceptable volume 
reduction. In our hands the procedure does not lead to 
complete obliteration of the cyst but rather prevents it from 
expanding. For example, we were able to decrease large 
liver cysts (>20 cm) to less than 5 cm with adequate 
symptom control.
We used a questionnaire to score the severity of symp­
toms. Overall, there was an average decrease in the severity 
of symptoms. Abdominal distension and postprandial 
fullness were among the symptoms that were scored, in 
both groups, as most severe before treatment. These 
symptoms decreased after treatment. Moreover, most 
patients experience pain relief.
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Apart from pain, we observed no complications such as 
infection of liver cysts or pleural fluid effusion [16]. Pain 
could occur at any time during the procedure—when the 
catheter passes the liver capsule, upon fluid aspiration, and, 
finally, after injection of ethanol in the cyst. Patients 
describe the pain during ethanol instillation as a burning, 
but in most instances that abates quickly. Pain is seen in all 
studies as most common drawback of aspiration [12, 14, 
16, 21- 26].
Aspiration-sclerotherapy has several advantages over 
other approaches, because it is easy, can be performed on 
an out-patient basis and leads to few complications [14, 
27]. Our procedure has similarities to, and differences 
from, sclerotherapy described elsewhere [12, 14, 16, 21­
26, 28]. Similar to many other studies we used ethanol as 
sclerosing agent. It destroys the lining epithelium and leads 
to fibrotic obliteration which will impede production of 
cyst fluid [12]. Other sclerosing agents such as minocy­
cline, tetracycline, or doxycycline destroy the lining 
epithelium by virtue of the highly acidic pH [14, 15]. These 
agents appeared to be similarly effective to ethanol [16]. A 
risk of the use of a sclerosing agent such as ethanol is 
marked sclerosis of the bile ducts when it is injected into a 
cyst that communicates with the biliary tree [12]. Therefore 
some authors argue that fluoroscopy should be used prior to 
instillation of ethanol [12, 16, 22, 23, 25, 28, 29]. We 
treated superficially located cysts that are not likely to 
communicate with the biliary tree, hence avoiding the need 
for verification by fluoroscopy. There is lack of objective 
data concerning optimum exposure time. Some authors 
instill ethanol for prolonged period but we chose a limited 
exposure time in order to limit the chances for complica­
tions [12, 14, 16, 22- 26]. This is supported by another 
study that elected to leave a catheter for drainage after the 
sclerotherapy. The sclerotherapy was repeated if more than 
10-15 ml cyst fluid was produced. In contrast with our 
findings, this study reports complications such as infection 
and pleural fluid effusion [16]. Most likely, these compli­
cations could have been avoided if the catheter was 
removed immediately after sclerotherapy. Several studies 
reported that the patients need to be turned over to various 
positions, in order to permit ethanol to come into contact 
with all surfaces of the cyst cavity [12, 14, 15, 22, 23, 25, 
26, 28]. This procedure was not part of our applied 
technique.
Aspiration-sclerotherapy is indicated in patients with 
symptoms that are associated with large liver cysts 
(>5 cm) and/or dominant cysts.
Other patients, especially those with multiple small 
cysts scattered throughout the liver parenchyma, are can­
didates for other therapeutic options—open or laparoscopic 
liver cyst fenestration, partial liver resection, or liver 
transplantation.
The choice between these modalities is made on the 
basis of the location of cysts, volume of the liver, and 
surgical experience. Open fenestration of cysts is more 
effective in terms of volume reduction, but the morbidity of 
laparoscopic fenestration is lower than that of the open 
procedure [30]. Patients with livers with a dominantly 
affected liver segment might be candidates for a partial 
liver resection, but the morbidity rate is higher than for the 
other procedures. Finally, liver transplantation is indicated 
if other therapies are no option or failed and if the patient is 
severely incapacitated by the large volume of the liver [10].
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